Scibase AB - Asset Resilience Ratio
Scibase AB (SCIB) has an Asset Resilience Ratio of 43.33% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Scibase AB (SCIB) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Scibase AB's Asset Resilience Ratio has changed over time. See how leveraged is Scibase AB's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Scibase AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Scibase AB stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr22.60 Million | 43.33% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr22.60 Million | 43.33% |
Asset Resilience Insights
- Very High Liquidity: Scibase AB maintains exceptional liquid asset reserves at 43.33% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Scibase AB Industry Peers by Asset Resilience Ratio
Compare Scibase AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
Annual Asset Resilience Ratio for Scibase AB (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Scibase AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.33% | Skr22.60 Million ≈ $2.43 Million |
Skr52.17 Million ≈ $5.61 Million |
+25.11pp |
| 2024-12-31 | 18.22% | Skr11.24 Million ≈ $1.21 Million |
Skr61.73 Million ≈ $6.64 Million |
-34.82pp |
| 2023-12-31 | 53.04% | Skr34.12 Million ≈ $3.67 Million |
Skr64.33 Million ≈ $6.92 Million |
+15.26pp |
| 2022-12-31 | 37.77% | Skr18.83 Million ≈ $2.03 Million |
Skr49.85 Million ≈ $5.37 Million |
-39.00pp |
| 2021-12-31 | 76.77% | Skr65.61 Million ≈ $7.06 Million |
Skr85.46 Million ≈ $9.20 Million |
+6.86pp |
| 2020-12-31 | 69.92% | Skr41.43 Million ≈ $4.46 Million |
Skr59.25 Million ≈ $6.38 Million |
+12.61pp |
| 2019-12-31 | 57.31% | Skr26.46 Million ≈ $2.85 Million |
Skr46.16 Million ≈ $4.97 Million |
-25.92pp |
| 2018-12-31 | 83.23% | Skr67.51 Million ≈ $7.27 Million |
Skr81.11 Million ≈ $8.73 Million |
-2.77pp |
| 2017-12-31 | 86.01% | Skr110.02 Million ≈ $11.84 Million |
Skr127.91 Million ≈ $13.77 Million |
+2.81pp |
| 2016-12-31 | 83.20% | Skr84.95 Million ≈ $9.14 Million |
Skr102.11 Million ≈ $10.99 Million |
+78.75pp |
| 2012-12-31 | 4.45% | Skr1.06 Million ≈ $114.31K |
Skr23.87 Million ≈ $2.57 Million |
-- |
About Scibase AB
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more